Eric Joseph
Stock Analyst at JP Morgan
(2.07)
# 2,979
Out of 5,124 analysts
124
Total ratings
39.29%
Success rate
-4.37%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $4.55 | +141.76% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $29.41 | +66.61% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $28.34 | +62.31% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $73.46 | -12.88% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.54 | +97.74% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.70 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.44 | -5.91% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $76.70 | -12.65% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.32 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.28 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $17.43 | +72.12% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $5.96 | +134.90% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $79.85 | -11.08% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $25.45 | +49.31% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $5.99 | +283.97% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $15.15 | +12.21% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $8.17 | +157.04% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.58 | -26.36% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.26 | +1,090.48% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.03 | +195.57% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $16.01 | -31.29% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $25.73 | +288.65% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.90 | +455.56% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.41 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $38.32 | -71.29% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $19.78 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $7.35 | +1,532.65% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $8.76 | +3,324.66% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $13.53 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $2.00 | +350.00% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.47 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.60 | +1,515.38% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $4.30 | +202.33% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.44 | +2,376.92% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $4.55
Upside: +141.76%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $29.41
Upside: +66.61%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $28.34
Upside: +62.31%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $73.46
Upside: -12.88%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.54
Upside: +97.74%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.70
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.44
Upside: -5.91%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $76.70
Upside: -12.65%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.32
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $17.43
Upside: +72.12%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.96
Upside: +134.90%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $79.85
Upside: -11.08%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $25.45
Upside: +49.31%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $5.99
Upside: +283.97%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $15.15
Upside: +12.21%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $8.17
Upside: +157.04%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $13.58
Upside: -26.36%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.26
Upside: +1,090.48%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.03
Upside: +195.57%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $16.01
Upside: -31.29%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $25.73
Upside: +288.65%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.90
Upside: +455.56%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.41
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $38.32
Upside: -71.29%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $19.78
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $7.35
Upside: +1,532.65%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $8.76
Upside: +3,324.66%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $13.53
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $2.00
Upside: +350.00%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.47
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.60
Upside: +1,515.38%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $4.30
Upside: +202.33%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.44
Upside: +2,376.92%